Biosimilar Red Tape Elimination Act
Summary
The Biosimilar Red Tape Elimination Act (S.1954) was reported favorably out of the Senate HELP Committee, reducing regulatory barriers for biosimilar interchangeability. This increases competitive pressure on innovator biologic drugs from AbbVie, Johnson & Johnson, Merck, and Eli Lilly, with no direct funding or appropriation involved.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The bill eliminates a key regulatory hurdle for biosimilar interchangeability, accelerating competition for top-selling biologics.
- 2.Direct revenue risk to $MRK (Keytruda, ~$25B), $JNJ (Stelara, ~$10B), $LLY (Trulicity, ~$7B), and $ABBV (Skyrizi, ~$4B).
- 3.No direct federal spending; impact is purely through market competition dynamics.
Market Implications
The regulatory easing will compress margins and market share for innovator biologic drugs, particularly those with large revenue bases like Keytruda and Stelara. Investors should monitor legislative progress; any floor action or passage will generate negative sentiment for , , , and $ABBV. Conversely, biosimilar-focused firms (e.g., $AMGN, though not in our dataset) would benefit. The bill's impact is purely structural—no immediate financial catalyst until passage.
Full Analysis
On June 17, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered S.1954, the Biosimilar Red Tape Elimination Act, to be reported favorably with an amendment. The bill streamlines the process for biosimilars to be deemed interchangeable with reference biologics under the Public Health Service Act, removing the requirement for separate interchangeability studies. It was introduced by Sen. Mike Lee (R-UT) with five cosponsors and has a companion bill in the House (H.R. 5526).
The bill does not authorize or appropriate any funding; its impact is purely regulatory. By lowering the evidentiary threshold for interchangeability, it accelerates the timeline and reduces costs for biosimilar manufacturers to gain market access, directly eroding the pricing power and market share of innovator biologic drugs. No new spending is created—the mechanism is a deregulatory mandate on the FDA.
Structural losers are the major biologic innovators among the provided tickers: (Keytruda), (Stelara), (Trulicity), and $ABBV (Skyrizi). These drugs represent a combined revenue at risk exceeding $40B. faces a mixed but net negative impact given its limited innovator biologic exposure and small biosimilar offset. Winners are biosimilar manufacturers, but no pure-play biosimilar companies are among the provided tickers. The bill also benefits payers like $UNH (health insurers) by reducing drug costs, but that effect is indirect and secondary.
Timeline: The bill must pass the full Senate, the House, and be signed by The President. With strong bipartisan sponsorship (cosponsors from both parties) and a companion bill, passage probability is moderate to high in the current Congress. Floor action is expected in the coming months.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Elimination of separate interchangeability study requirement for biosimilars under Section 351(k) of the Public Health Service Act
Who must act
FDA
What happens
Biosimilar manufacturers can obtain interchangeability designation with lower evidentiary burden, increasing substitution threat for innovator biologics
Stock impact
AbbVie's biologic revenue from Skyrizi (risankizumab, ~$4B FY2025 est.) faces accelerated biosimilar entry, reducing market share and pricing power
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
A bill to amend the Federal Food, Drug, and Cosmetic Act to deem certain substances to be unsafe for use as food contact substances, and for other purposes.
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.